Table 2
Open in new tab

Inclusion body myositis-associated conditions

IBM
(n = 50)		IIM
(n = 65)		Controls
(n = 294)
Neurological
Dementia3 (6)7 (10.8)31 (10.5)
Parkinson’s disease2 (4)2 (3.1)17 (5.8)
Peripheral neuropathy**18 (36)15 (23.1)51 (17.4)**
Conditions that may cause a peripheral neuropathy:

  • Diabetes mellitus*

16(32)19(29)129(44)

  • Hypo/Hyperthyroidism*

11(22)31(48)**87(30)

  • Vitamin B12 deficiency

3(6)3(5)8(3)

  • Monoclonal gammopathy of uncertain significance

4(8)1(2)8(3)#
Rheumatological
 Lupus erythematous***06(9)*1(<1)
 Systemic scleroderma***1(2)7(11)0
 Sjögren syndrome*3(6)2(3)3(1)*
 RA*4(8)8(12)13(5)
 Any of the above***8(16)19(29)15(5)**
Malignancies
 Malignancy of any type20 (40)23 (35.4)92 (31.3)
 Solid cancers16 (32)21 (32.3)88 (29.9)
 Haematologic malignancies*5 (10)3 (4.6)8 (2.7)*

  • Lymphoma

Diffuse large B cell (1)

Marginal zone (1)

Hodgkin’s (1)

Waldenstrom (1) Diffuse large B cell (1)

Difffuse large B cell (4)

Marginal zone (1)

  • Leukaemia

TLGL(2)0CLL(1)

  • Myeloma

Multiple myeloma (1)00

  • Myelodysplastic syndrome

002
Infectious
 Hepatitis B0 00 02 (0.7)
 Hepatitis C0 01 (1.5)2 (0.7)
 HIV0 00000
IBM
(n = 50)		IIM
(n = 65)		Controls
(n = 294)
Neurological
Dementia3 (6)7 (10.8)31 (10.5)
Parkinson’s disease2 (4)2 (3.1)17 (5.8)
Peripheral neuropathy**18 (36)15 (23.1)51 (17.4)**
Conditions that may cause a peripheral neuropathy:

  • Diabetes mellitus*

16(32)19(29)129(44)

  • Hypo/Hyperthyroidism*

11(22)31(48)**87(30)

  • Vitamin B12 deficiency

3(6)3(5)8(3)

  • Monoclonal gammopathy of uncertain significance

4(8)1(2)8(3)#
Rheumatological
 Lupus erythematous***06(9)*1(<1)
 Systemic scleroderma***1(2)7(11)0
 Sjögren syndrome*3(6)2(3)3(1)*
 RA*4(8)8(12)13(5)
 Any of the above***8(16)19(29)15(5)**
Malignancies
 Malignancy of any type20 (40)23 (35.4)92 (31.3)
 Solid cancers16 (32)21 (32.3)88 (29.9)
 Haematologic malignancies*5 (10)3 (4.6)8 (2.7)*

  • Lymphoma

Diffuse large B cell (1)

Marginal zone (1)

Hodgkin’s (1)

Waldenstrom (1) Diffuse large B cell (1)

Difffuse large B cell (4)

Marginal zone (1)

  • Leukaemia

TLGL(2)0CLL(1)

  • Myeloma

Multiple myeloma (1)00

  • Myelodysplastic syndrome

002
Infectious
 Hepatitis B0 00 02 (0.7)
 Hepatitis C0 01 (1.5)2 (0.7)
 HIV0 00000

P = comparison of the three groups; NS: not significant with P >0.05, P1 = IBM vs IIM, P2 = IBM vs Categorical variables are displayed as n (percentage). The P-value corresponding to comparison of the three groups is shown in the first column, P-value for IBM vs IIM group is shown in ‘IIM’ column, and P-value for IBM vs population controls is shown in ‘population controls’ column.

*

0.01≤P-value < 0.05;

**

P-value <0.01;

***

P-value <0.001;

****

P-value <0.0001;

#

P-value = 0.06.

IBM: inclusion body myositis; IIM: inflammatory myopathy.

Table 2
Open in new tab

Inclusion body myositis-associated conditions

IBM
(n = 50)		IIM
(n = 65)		Controls
(n = 294)
Neurological
Dementia3 (6)7 (10.8)31 (10.5)
Parkinson’s disease2 (4)2 (3.1)17 (5.8)
Peripheral neuropathy**18 (36)15 (23.1)51 (17.4)**
Conditions that may cause a peripheral neuropathy:

  • Diabetes mellitus*

16(32)19(29)129(44)

  • Hypo/Hyperthyroidism*

11(22)31(48)**87(30)

  • Vitamin B12 deficiency

3(6)3(5)8(3)

  • Monoclonal gammopathy of uncertain significance

4(8)1(2)8(3)#
Rheumatological
 Lupus erythematous***06(9)*1(<1)
 Systemic scleroderma***1(2)7(11)0
 Sjögren syndrome*3(6)2(3)3(1)*
 RA*4(8)8(12)13(5)
 Any of the above***8(16)19(29)15(5)**
Malignancies
 Malignancy of any type20 (40)23 (35.4)92 (31.3)
 Solid cancers16 (32)21 (32.3)88 (29.9)
 Haematologic malignancies*5 (10)3 (4.6)8 (2.7)*

  • Lymphoma

Diffuse large B cell (1)

Marginal zone (1)

Hodgkin’s (1)

Waldenstrom (1) Diffuse large B cell (1)

Difffuse large B cell (4)

Marginal zone (1)

  • Leukaemia

TLGL(2)0CLL(1)

  • Myeloma

Multiple myeloma (1)00

  • Myelodysplastic syndrome

002
Infectious
 Hepatitis B0 00 02 (0.7)
 Hepatitis C0 01 (1.5)2 (0.7)
 HIV0 00000
IBM
(n = 50)		IIM
(n = 65)		Controls
(n = 294)
Neurological
Dementia3 (6)7 (10.8)31 (10.5)
Parkinson’s disease2 (4)2 (3.1)17 (5.8)
Peripheral neuropathy**18 (36)15 (23.1)51 (17.4)**
Conditions that may cause a peripheral neuropathy:

  • Diabetes mellitus*

16(32)19(29)129(44)

  • Hypo/Hyperthyroidism*

11(22)31(48)**87(30)

  • Vitamin B12 deficiency

3(6)3(5)8(3)

  • Monoclonal gammopathy of uncertain significance

4(8)1(2)8(3)#
Rheumatological
 Lupus erythematous***06(9)*1(<1)
 Systemic scleroderma***1(2)7(11)0
 Sjögren syndrome*3(6)2(3)3(1)*
 RA*4(8)8(12)13(5)
 Any of the above***8(16)19(29)15(5)**
Malignancies
 Malignancy of any type20 (40)23 (35.4)92 (31.3)
 Solid cancers16 (32)21 (32.3)88 (29.9)
 Haematologic malignancies*5 (10)3 (4.6)8 (2.7)*

  • Lymphoma

Diffuse large B cell (1)

Marginal zone (1)

Hodgkin’s (1)

Waldenstrom (1) Diffuse large B cell (1)

Difffuse large B cell (4)

Marginal zone (1)

  • Leukaemia

TLGL(2)0CLL(1)

  • Myeloma

Multiple myeloma (1)00

  • Myelodysplastic syndrome

002
Infectious
 Hepatitis B0 00 02 (0.7)
 Hepatitis C0 01 (1.5)2 (0.7)
 HIV0 00000

P = comparison of the three groups; NS: not significant with P >0.05, P1 = IBM vs IIM, P2 = IBM vs Categorical variables are displayed as n (percentage). The P-value corresponding to comparison of the three groups is shown in the first column, P-value for IBM vs IIM group is shown in ‘IIM’ column, and P-value for IBM vs population controls is shown in ‘population controls’ column.

*

0.01≤P-value < 0.05;

**

P-value <0.01;

***

P-value <0.001;

****

P-value <0.0001;

#

P-value = 0.06.

IBM: inclusion body myositis; IIM: inflammatory myopathy.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close